CPX-351 Is Effective in Newly Diagnosed Older Patients with AML and with Multiple Risk Factors

被引：0
|
作者：
Lancet, Jeffrey E. [1 ]
Cortes, Jorge E. [2 ]
Kovacsovics, Tibor [3 ]
Hogge, Donna E. [4 ]
Kolitz, Jonathan E. [5 ]
Tallman, Martin S. [6 ]
Hoering, Antje [7 ]
Chiarella, Michael T. [8 ]
Louie, Arthur C. [8 ]
Feldman, Eric [9 ]
机构：
[1] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[3] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA
[4] Univ British Columbia, Div Hematol & Leukemia BMT, Vancouver, BC V5Z 1M9, Canada
[5] Hofstra N Shore LIJ Sch Med, Hempstead, NY USA
[6] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[7] Canc Res & Biostat, Res & Biostat, Seattle, WA USA
[8] Celator Pharmaceut, Princeton, NJ USA
[9] Weill Cornell Med Coll, New York, NY USA
来源：
BLOOD | 2012年 / 120卷 / 21期
关键词：
D O I：
10.1182/blood.V120.21.3626.3626
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3626
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Safety and feasibility of outpatient induction chemotherapy with CPX-351 in selected older adult patients with newly diagnosed AML.
    Kubal, Timothy Edward
    Salamanca, Christopher
    Komrokji, Rami S.
    Sallman, David A.
    Sweet, Kendra Lynn
    Padron, Eric
    List, Alan F.
    Lancet, Jeffrey E.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [2] Transplant outcomes after CPX-351 vs 7+3 in older adults with newly diagnosed high-risk and/or secondary AML
    Uy, Geoffrey L.
    Newell, Laura F.
    Lin, Tara L.
    Goldberg, Stuart L.
    Wieduwilt, Matthew J.
    Ryan, Robert J.
    Faderl, Stefan
    Lancet, Jeffrey E.
    BLOOD ADVANCES, 2022, 6 (17) : 4989 - 4993
  • [3] A comparison of CR versus CRi response following CPX-351 treatment of newly diagnosed AML in elderly patients (pts)
    Lancet, Jeffrey E.
    Cortes, Jorge E.
    Kovacsovics, Tibor
    Hogge, Donna
    Kolitz, Jonathan E.
    Tallman, Martin S.
    Chiarella, Michael
    Louie, Arthur Chin
    Feldman, Eric Jay
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [4] Older adults with newly diagnosed high-risk/secondary AML who achieved remission with CPX-351: phase 3 post hoc analyses
    Lin, Tara L.
    Rizzieri, David A.
    Ryan, Daniel H.
    Schiller, Gary J.
    Kolitz, Jonathan E.
    Uy, Geoffrey L.
    Hogge, Donna E.
    Solomon, Scott R.
    Wieduwilt, Matthew J.
    Ryan, Robert J.
    Faderl, Stefan
    Cortes, Jorge E.
    Lancet, Jeffrey E.
    BLOOD ADVANCES, 2021, 5 (06) : 1719 - 1728
  • [5] Final results of a phase III randomized trial of CPX-351 versus 7+3 in older patients with newly diagnosed high risk (secondary) AML.
    Lancet, Jeffrey E.
    Uy, Geoffrey L.
    Cortes, Jorge E.
    Newell, Laura F.
    Lin, Tara L.
    Ritchie, Ellen K.
    Stuart, Robert K.
    Strickland, Stephen Anthony
    Hogge, Donna
    Solomon, Scott R.
    Stone, Richard M.
    Bixby, Dale L.
    Kolitz, Jonathan E.
    Schiller, Gary J.
    Wieduwilt, Matthew Joseph
    Ryan, Daniel H.
    Hoering, Antje
    Chiarella, Michael
    Louie, Arthur Chin
    Medeiros, Bruno C.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [6] Outcomes in Older Patients with Newly Diagnosed High-Risk/Secondary AML (sAML) who Achieve Remission with CPX-351 versus 7+3 Induction
    Faderl, S.
    Uy, G. L.
    Schiller, G. J.
    Cortes, J. E.
    Ritchie, E. K.
    Ryan, R. J.
    Chiarella, M.
    Louie, A. C.
    ANNALS OF HEMATOLOGY, 2019, 98 : S39 - S40
  • [7] CPX-351 in Patients with Newly Diagnosed Post Myeloproliferative Neoplasms Acute Myeloid Leukemia
    Garciaz, Sylvain
    Belhabri, Amine
    Guieze, Romain
    Goursaud, Laure
    Peterlin, Pierre
    Ledoux, Marie-Pierre
    Mathilde, Hunault-Berger
    Chebrek, Safia
    Robin, Jean-Baptiste
    Pigneux, Arnaud
    Bonnet, Sarah
    Bonmati, Caroline
    Bertoli, Sarah
    Braun, Thorsten
    Chantepie, Sylvain
    Meunier, Mathieu
    Heiblig, Mael
    Cluzeau, Thomas
    Jourdan, Eric
    Villate, Alban
    Recher, Christian
    Vey, Norbert
    Rey, Jerome
    BLOOD, 2023, 142
  • [8] CPX-351 As First Intensive Therapy for Elderly Patients with AML
    Ritchie, Ellen K.
    Miah, Sumaiya K.
    Lee, Sangmin
    Curcio, Tania
    Desai, Pinkal
    Ball, Jeffrey
    Samuel, Michael B.
    Roboz, Gail J.
    BLOOD, 2019, 134
  • [9] Comprehensive Molecular Stratification of Patients with AML Treated with CPX-351
    Ho, Thuy
    Gor, Juhi
    Murray, Graeme
    Bouligny, Ian
    Maher, Keri
    BLOOD, 2023, 142
  • [10] 19 courses of CPX-351 for the treatment of AML
    Boyd, S.
    McMullin, M. F.
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 : 189 - 190
12345